Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Velcade + Rituximab in Relapsed/Progressed Follicular Lymphoma
NCT01830465Phase 2Completed
- Sponsor
- Gruppo Italiano Studio Linfomi
- Start
- Aug 2006
- Primary completion
- Aug 2008
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in follicular lymphoma (FL), sponsored by Gruppo Italiano Studio Linfomi. Primary endpoint: Antitumor activity after complete treatment. Started Aug 2006; status: completed.
02
Drugs
bortezomib
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT01830465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01830465.